Dr. Glass is the Co-founder of Advantia Health. He has an extensive background as both a thought leader and experienced practitioner in ambulatory anesthesia and the pharmacology of analgesics.
Prior to Advantia, Dr. Glass was Professor and Chairman of the Department of Anesthesiology at the State University of New York at Stony Brook. Throughout his career, he has been intimately involved in the growth of ambulatory surgery, both through his research and through his roles on the Board of the Society for Ambulatory Anesthesia (SAMBA), where he was also President in 2010. In 2015, Dr. Glass received the SAMBA Distinguished Service Award, the highest honor bestowed by SAMBA.
Prior to Stony Brook, Dr. Glass pursued an academic career in anesthetic pharmacology which led to his appointment as Professor with Tenure at Duke University Medical Center in Durham, North Carolina. Nearly all of the SAFE (short-acting, fast-emergence) drugs in use today were studied and made popular in ambulatory anesthesia by Dr. Glass and his team at Duke University, including propofol, remifentanil, ondansetron, alfentanil, midazolam, and vecuronium.
For 8 years, Dr. Glass was Section Editor for Ambulatory Anesthesia for the Journal of Anesthesia & Analgesia. He has also been a consultant for multiple pharmaceutical and device companies seeking to delve into ambulatory surgery and office-based procedures, and has been involved in consulting several disruptive technologies such as the Bispectral Monitor, Target Controlled infusion devices and, most recently, with Johnson & Johnson on the development of Sedasys.